Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-169 in Diabetic Macular Edema
NCT07429474Phase 1Not yet recruiting
- Sponsor
- Laboratorios Sophia
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PRO-169 in diabetic macular edema (DME), sponsored by Laboratorios Sophia. Primary endpoint: Proportion of patients with positive serum anti-drug antibodies for bevacizumab at Day 90. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
PRO-169
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT07429474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429474.